Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of alzheimer disease

Molecular Therapy

Volumn 17, Issue 8, 2009, Pages 1381-1386

  Liu, Yinxing ^a   Studzinski, Christa ^a   Beckett, Tina ^a   Guan, Hanjun ^a   Hersh, Matthew A ^b   Murphy, M Paul ^a   Klein, Ronald ^c   Hersh, Louis B ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; MEMBRANE METALLOENDOPEPTIDASE;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; ANIMAL; ARTICLE; BRAIN; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HINDLIMB; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; SKELETAL MUSCLE; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; BRAIN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENE THERAPY; HINDLIMB; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; NEPRILYSIN;

EID: 70350728321     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.115     Document Type: Article

References (25)

1. Selkoe, DJ (1994). Cell biology of the amyloid β -protein precursor and the mechanism of Alzheimer’s disease. Annu Rev Cell Biol 10: 373-403.
2. Leissring, MA, Farris, W, Chang, AY, Walsh, DM, Wu, X, Sun, X et al. (2003). Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40: 1087-1093.
3. Marr, RA, Rockenstein, E, Mukherjee, A, Kindy, MS, Hersh, LB, Gage, FH et al. (2003). Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23: 1992-1996.
4. Hemming, ML, Patterson, M, Reske-Nielsen, C, Lin, L, Isacson, O and Selkoe, DJ (2007). Reducing amyloid plaque burden via ex vivo gene delivery of an A β ‑degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med 4: e262.
5. Deane, R, Du Yan, S, Submamaryan, RK, LaRue, B, Jovanovic, S, Hogg, E et al. (2003). RAGE mediates amyloid- β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913.
6. Deane, R, Wu, Z, Sagare, A, Davis, J, Du Yan, S, Hamm, K et al. (2004). LRP/amyloid β -peptide interaction mediates differential brain efflux of A β isoforms. Neuron 43: 333-344.
7. Oddo, S, Caccamo, A, Smith, IF, Green, KN and LaFerla, FM (2006). A dynamic relationship between intracellular and extracellular pools of A β. Am J Pathol 168: 184-194.
8. DeMattos, RB, Bales, KR, Cummins, DJ, Dodart, JC, Paul, SM and Holtzman, DM (2001). Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 98: 8850-8855.
9. Tseng, BP, Esler, WP, Clish, CB, Stimson, ER, Ghilardi, JR, Vinters, HV et al. (1999). Deposition of monomeric, not oligomeric, A β mediates growth of Alzheimer’s disease amyloid plaques in human brain preparations. Biochemistry 38: 10424-10431.
10. DeMattos, RB, Bales, KR, Cummins, DJ, Paul, SM and Holtzman, DM (2002). Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science 295: 2264-2267.
11. Bard, F, Cannon, C, Barbour, R, Burke, RL, Games, D, Grajeda, H et al. (2000). Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919.
12. Matsuoka, Y, Saito, M, LaFrancois, J, Saito, M, Gaynor, K, Olm, V et al. (2003). Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to β -amyloid. J Neurosci 23: 29-33.
13. Park, JH, Widi, GA, Gimbel, DA, Harel, NY, Lee, DH and Strittmatter, SM (2006). Subcutaneous Nogo receptor removes brain amyloid- β and improves spatial memory in Alzheimer’s transgenic mice. J Neurosci 26: 13279-13286.
14. Sagare, A, Deane, R, Bell, RD, Johnson, B, Hamm, K, Pendu, R et al. (2007). Clearance of amyloid- β by circulating lipoprotein receptors. Nat Med 13: 1029-1031.
15. Oddo, S, Caccamo, A, Shepherd, JD, Murphy, MP, Golde, TE, Kayed, R et al. (2003). Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular A β and synaptic dysfunction. Neuron 39: 409-421.
16. Guan, H, Liu, Y, Daily, A, Police, S, Kim, MH, Oddo, S et al. (2009). Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer’s disease. J Neurosci Res 87: 1462-1473.
17. Sheikh, IA and Kaplan, AP (1989). Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensinconverting enzyme and determination of final degradation products. Biochem Pharmacol 38: 993-1000.
18. Rivière, C, Danos, O and Douar, AM (2006). Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 13: 1300-1308.
19. Klein, RL, Dayton, RD, Leidenheimer, NJ, Jansen, K, Golde, TE and Zweig RM (2006). Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 13: 517-527.
20. Thompson, MW, Govindaswami, M and Hersh, LB (2003). Mutation of active site residues of the puromycin-sensitive aminopeptidase: conversion of the enzyme into a catalytically inactive binding protein. Arch Biochem Biophys 413: 236-242.
21. Daily, A, Nath, A and Hersh, LB (2006). Tat peptides inhibit neprilysin. J Neurovirol 12: 153-160.
22. Cassis, LA, Helton, MJ, Howatt, DA, King, VL and Daugherty, A (2005). Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Br J Pharmacol 144: 443-448.
23. McGowan, E, Pickford, F, Kim, J, Onstead, L, Eriksen, J, Yu, C et al. (2005). A β 42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47: 191-199.
24. Murphy, MP, Beckett, TL, Ding, Q, Patel, E, Markesbery, WR, St Clair, DK et al. (2007). A β solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 27: 301-311.
25. Oddo, S, Vasilevko, V, Caccamo, A, Kitazawa, M, Cribbs, DH and LaFerla, FM (2006). Reduction of soluble A β and tau, but not soluble A β alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281: 39413-39423.